Key facts
- Solaxa’s last known valuation is $38.0M (Dec 2024).
- It has raised $5.0M across 4 recorded rounds; the latest was Seed Round ($305K) in Aug 2024.
- Notable investors include TEDCO, Angel Star Ventures, DMV Angel Group, Rochester Angel Network.
- Solaxa has filed 4 Form Ds with the SEC, most recently Sep 2024 ($305K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Solaxa
Funding rounds
4 roundsAbout Solaxa
Developer of a biopharmaceutical company intended to provide innovative treatments to address patients with rare neurodegenerative diseases and nerve injuries caused by chemotherapy and trauma. The company offers a potent class of ion channel blockers that can detect and treat neuronal dysfunction, particularly aminopyridines, to restore nerve function, enabling users to potentially develop treatments for a wider range of neurological conditions, aiming to improve the lives of patients globally.
- Sector
- Healthcare
- HQ
- Bethesda, MD, United States
- Founded
- 2021
- Employees
- 10
- Website
- solaxa.com/
- Ownership
- Privately Held (backing)
Solaxa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solaxa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solaxa in its N-PORT filings yet. We sweep new filings monthly.